Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).
Pharmacy firm eyes 2024 rollout of 1st targeted PET imaging agent for kidney cancer
1 year ago
39
Related
Popular
Reduce your risk of cancer: get involved and have fun
1 year ago
227
English (US) · Copyright © 2019 - 2025 | Whatiscancer.net | All Rights Reserved.